Our outcome of interest is endoscopic procedure utilization, defined as any type or amount of endoscopic procedure use over each 3-year period.
Through the use of the Premier research database, we were able to access detailed inpatient information, including drug treatment, procedure utilization, and patients' diagnoses.
The other procedures also had considerably lower product units per procedure utilization for ORCs compared to OAHs (31%, 18%, and 16% lower for cardiovascular procedures, cholecystectomy, and hysterectomy, respectively; P<0.001 for all three procedure types).
Although the Premier Research Database captures detailed information on inpatient drug treatment and procedure utilization, laboratory testing, and patients' diagnoses, this is administrative information collected for billing purposes and not expressly for research, and it thus lacks certain relevant clinical details.
We calculated age-stratified procedure utilization rates by using the U.S. Census Bureau 2000-based postcestimatesimates of the civilian population as of July, 1, 2006 for age-groups 15 years and older [ 19].
This finding holds true across three Canadian jurisdictions, and over time, and its implications are relevant to the planning of cardiac procedure utilization not only in Canada, but also in countries with both lower and higher population rates of cardiac catheterization.
Utilization of a specific dental procedure was defined as the presence of a claim for such procedure and utilization rates for treatment procedures were calculated based on the number of enrollees who had at least one procedure in a year.
Trends for these two procedures regarding utilization, revision procedures, and other demographic information have not been sufficiently explored.
These databases typically capture medical diagnoses, procedures, drug utilization, hospitalizations, costs and mortality.
Hemostatic endpoints included cessation of acute bleeding, prevention of bleeding during interventional procedures and utilization of alternative blood component replacement therapies within six hours pre- and post-PCC application.
